Insights to Cure Disease and Heal Healthcare
Understand the power of causal machine learning and why it’s different than other AI solutions for driving precision medicine and discovering what works for whom.
GNS Healthcare applies its groundbreaking, powerful artificial intelligence (AI) platform to unravel the complexity of human disease in order to match the right treatment to the right patient at the right time.
We work with leading biopharma companies to accelerate and optimize drug discovery, development and commercialization. Our platform leverages both clinical trial data and real world data (RWD) to model patient response to treatment in silico. These insights enable biopharma to discover which subpopulations of patients respond, which do not and more importantly understand why, directly from the data and without bias. These models can also be used to conduct in silico clinical trials generating real world evidence of a drug’s value in the real world, both before and after launch.
We partner with innovative health plans to identify which members will respond to which drug and care management interventions at what point in time. Our platform provides a prescriptive approach allowing health plans to understand the effectiveness of specific interventions, member by member.
We work with progressive patient foundations to discover novel disease pathways and drug targets to accelerate the development of new therapeutics.
By leveraging the most powerful form of AI, called causal machine learning, we transform massive and diverse data streams to precisely match therapeutics, procedures, and care management interventions to individuals to dramatically improve health outcomes and reduce the total cost of care. We have modeled over forty diseases in the areas of oncology, cardiovascular and metabolic, neurology, autoimmune and others.
We understand that in order to make precision medicine a reality, we need to discover and deliver novel insights that will cure disease and heal the healthcare system.
OUR AI PLATFORM: REFS™
REFS (Reverse Engineering Forward Simulation) uncovers the cause and effect relationships from data at scale to solve healthcare’s matching problem and make precision medicine a reality.
Speed to discovery
Our platform works by reconstructing complex diseases into computer models which allows users to simulate real world scenarios that take the guesswork out of critical decisions and increase the speed to discovery from years to months.
Transparency of results
By employing causal machine learning, our models not only deliver novel insights, they identify the underlying cause and effect relationships, crucial to understanding and treating the root cause of disease progression and patient response.
Unlimited data volume and variety
We transform and integrate millions of data points of all types – EMR, genetic, proteomic, genomic, claims, consumer, laboratory, prescription, mobile health, sociodemographic and more – revealing unforeseen relationships in a dynamic platform that continues to grow smarter over time.
Healthcare’s Most Powerful AI Solution
Understand the power of causal machine learning, why it’s different than other AI solutions and why it’s critical to transform biomedicine and healthcare. Check out video below to learn more.
GNS By The Numbers
We’re all about data points, numbers and evidence.
Complex Models Built
Data Points Modeled
Years Applying AI to Healthcare
Peer Reviewed Journal Articles & Posters
Can Personalized Medicine Be the Answer to Value-based Care?
by email@example.com (GNS Healthcare) on April 18, 2019 at 2:18 pm
There's been a lot of conversation around value-based care (VBC) models, and payers, providers and biopharma – each have their own take on […]
The Boston Marathon and AI: Running a Parallel Course
by firstname.lastname@example.org (GNS Healthcare) on April 11, 2019 at 1:21 pm
In 1896, the marathon returned to popularity as a competition in the Summer Olympic Games in Athens. The Olympic Games turned out to be […]
Biomarkers: The Guideposts for Drug Discovery and Development
by Brian Harms, Ph.D., VP, Precision Medicine on March 21, 2019 at 1:37 pm
Biomarker-guided precision medicine is increasingly important in drug discovery and development. Pharma products that incorporate biomarkers to […]
News & Events
Colin Hill speaks on AI and Machine Learning in Cancer Medicine at Milken Institute 2019 Global Conference
The panel will focus on uses of ‘artificial intelligence and machine learning’ for cancer early detection, diagnosis, drug development and clinical decision making. These technologies have the potential to accelerate our understanding of cancer at the cellular and the...read more
"AI is being used to really leverage learning from large-scale datasets, and those large-scale datasets are used to get to better novel targets." - Iya Khalil, GNS Co-Founder and COO, joins Mike May of Genetic Engineering & Biotechnology News to discuss AI in drug...read more
GNS Co-founder, Iya Khalil interviewed by BioCentury: A Frequentist and a Bayesian Walk Into a Trial
GNS Co-Founder and COO Iya Khalil weighed in on the stand-off between Bayesians and frequentist. Read the full piece here.read more
Improving The Probability of Success: New Tools in Drug Development
How robust data and powerful AI is changing the way drugs are developed.
Why BioPharma Needs AI to Succeed
Check out our infographic to see why biopharma needs AI to succeed.